A Randomized, Double-Blind, Placebo- and Moxifloxacin Positive-Controlled (Open-Label), Cross-Over Study to Evaluate the Potential Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2016
At a glance
- Drugs Moxifloxacin (Primary) ; Naltrexone/bupropion (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Orexigen Therapeutics; Takeda
- 31 Oct 2016 Status changed from active, no longer recruiting to completed.
- 27 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2016.
- 28 Apr 2016 Status changed from recruiting to active, no longer recruiting.